about
Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironmentComplement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects.Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemiaCAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery.The immunotherapy of prostate and bladder cancer.αB-Crystallin regulates expansion of CD11b⁺Gr-1⁺ immature myeloid cells during tumor progression.CD40L - a multipotent molecule for tumor therapy.CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes.Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy.CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer.AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial.Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines.Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment.Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma.Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition.AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model.In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue.T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis.T regulatory cells lacking CD25 are increased in MS during relapse.Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitroIL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myelomaA Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and LeukemiaEvaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma PatientsImmunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
P50
Q33718737-545F4C20-6C8E-4B8E-9833-09D384ADEECAQ33801802-F1FEFF37-E1E5-4412-8272-0365D4E49A7EQ34576982-7F6C81CE-2A29-4AA3-86D7-C5EAFD13F17BQ36112863-51C43A19-E358-4C50-B6F5-0D28368F13F4Q36249962-6E12A06B-2912-4DCF-9205-4FF3CBC75547Q36482872-658A1640-F83A-4335-9D11-C37BCA4A4E33Q36754727-BB424518-62C5-46B3-9641-55F35D720AD1Q39028768-5EC3E9E9-C874-44BA-BDDD-463190A2DD0CQ39707212-2A4446CD-EA3F-41CD-877C-E7FE784B70F8Q40313562-FB563A39-2888-4D2A-834A-F2C5F02750BFQ40366972-1E486262-1E8B-4D6C-AA9C-72A0DEF06B7CQ40477958-2E8F77AA-8B91-4199-B373-66E55A6CD109Q45858919-7A712624-B1BF-4D22-945C-E864A08A3269Q45864362-39F11034-9360-438C-94C3-7055B934E448Q45875424-36CE5706-5219-4291-A29D-CADE87245315Q45876555-C94D6907-E1E6-4625-A8D3-F8A69BF5B16CQ45888387-B4244E9C-0941-45EE-8D14-8B1BED1AF87CQ45889278-DA17F2E8-604D-4C34-AC78-A1B6529330BBQ45889330-9764ED81-7652-452B-88F6-11F3BE71DAF1Q50456698-B9942C40-AA51-43E8-A337-7F5FFB7983CBQ50898570-F0171E14-458A-49DC-AF13-B8FE17BA104BQ53331257-E47E0EA9-582B-412C-83E9-F9BFE5EEA52FQ61883561-2F9A67BA-D7A0-4075-B221-1211FFD14551Q64375208-ABF4EAD7-68C9-4DB0-A04E-1E42FDDEF169Q89992850-B5B39AA2-055F-4495-A9ED-7AAC93DFBAEBQ90878344-1C247C06-1B9D-4EE8-B9EB-4CE469E8C858Q91619852-76BF2BE8-92C2-4FBA-B7E5-9635B29503D5Q94474328-0CF86201-D765-45CD-940F-83BB7FC02603
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Angelica Loskog
@ast
Angelica Loskog
@en
Angelica Loskog
@es
Angelica Loskog
@nl
Angelica Loskog
@sl
type
label
Angelica Loskog
@ast
Angelica Loskog
@en
Angelica Loskog
@es
Angelica Loskog
@nl
Angelica Loskog
@sl
prefLabel
Angelica Loskog
@ast
Angelica Loskog
@en
Angelica Loskog
@es
Angelica Loskog
@nl
Angelica Loskog
@sl
P106
P1153
6506001205
P21
P31
P496
0000-0001-8583-6138